This report provides a clear explanation of the nature of innovation in medicines. A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.
According to the 1999 UK Department of Health consultation document, the fundamental purpose of the National Institute for Health and Clinical Excellence (NICE) was to reduce inequalities in access to innovative care and ensure more rapid access to medicines identified as being of value to the NHS. Since NICE’s debut in April 1999, several analyses have examined the uptake of technologies that have been considered by NICE, but no evidence has yet been published on whether and how NICE’s health technology appraisal (HTA) processes may have affected the speed of access to new treatments.
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK, explores the interdependence between publicly funded and charity funded medical research. In particular, it focuses on whether and how changes in the levels of government funding can affect private funding for charities, medical research and the UK economy as a whole.
This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development of the health care system affects the relevance and appropriate use of various types of HTA. The approach developed then is used to analyse the options for Brazil, China and Taiwan.
Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.
This report examines the effect of the European Union’s 1999 Regulation on Orphan Medicinal Products (OMPs) on the European economy and society. This study collected data on several indicators of activity, completed a confidential survey of companies developing OMP, concluded four case studies and undertook a literature review. The result is a rich tableau of data and information that describe the effects of the OMP Regulation in some detail. Findings include the following.
This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.
This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.
Mestre-Ferrandiz, J., Puig-Peiro, R. and Towse, A.
Ten member companies of the EFPIA HTA Task Force commissioned OHE consulting to provide research, data and analysis that would enable EFPIA both to support and develop its policy position and to contribute positively to the emerging dialogue around the development of HTA within Europe.
The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the extent of public and charitable biomedical research, the debate is particularly intense.